🔗 Share this article

As the United States undertakes historic changes to its immunization schedules, a particular individual appears somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by questioning Covid vaccinations throughout the global health crisis and has zeroed in on alleged deaths following COVID-19 vaccination in her short tenure at the Food and Drug Administration.

Planned Changes to Pediatric Immunization Program

Public health authorities had intended to announce radical changes to the pediatric vaccine schedule earlier this month, synchronizing the US with Denmark’s national calendar, it is understood – a major change that would place the US out of alignment with many the international standard with little proof for improved outcomes. The announcement has been postponed until the next year.

In place of the top vaccines chief, Høeg is listed to speak at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

A Shift at the Agency

Høeg's temporary position may indicate a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad strengthen their influence at the FDA – and it signals a greater focus upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for halting some childhood shot schedules in the US so as to align more like Denmark's approach, a society with nationalized medicine and a citizenry roughly the population of Wisconsin’s.

In her initial comments, she has kept her attention on vaccines – usually the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Expertise

The appointee has no apparent track record in drug development, approval processes or administrative roles, which has been standard for previous directors of the CBER. She has served at the FDA as a top consultant to the agency head and the vaccine center since earlier this year.

“She appears not to have the necessary background” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in leading a sizeable institution. She has no expertise in industry regulation.”

Former directors of the center would “grasp laws and regulations and the research of medication creation”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the sort of resume that prior appointees who led the center have had.”

CDER has an enormous workload at the FDA, Woodcock emphasized.

“Many people just focuses on the novel medication approvals, but the generic drug division clears thousands of generic medications. There’s a biosimilars program, non-prescription drug unit and so forth, and every single one need to be supervised,” Dr. Woodcock said. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

There is also, a substantial administrative element to the position, which manages over 5,000 employees. “It is a massive leadership role, if you execute it properly,” she said.

Official Statement and Controversial Policies

In response to concerns about Dr. Høeg's credentials and whether this appointment indicates increased cooperation among FDA leaders on immunizations, a spokesperson stated that the “inquiries rely on flawed premises”.

“Her experience matches the functions of her role,” the representative explained, noting the time Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s recently launched expedited review system, a contentious one-day medication authorization process that allegedly concerned her predecessors. “By what process are these medications being chosen for this fast-track system? Who makes the calls?” Howard questioned. “There’s a lot of secrecy happening at the FDA right now.”

Overall, he stated, “the FDA seems to be moving towards more relaxed regulations of all drugs, aside from immunizations.”

Public Past Work on Immunizations

Concerning vaccines, Høeg has a more documented, if troubling, past, Howard have noted. She published a analysis using non-validated public submissions to determine the frequency of myocarditis after COVID-19 immunization. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have modified findings to imply COVID-19 vaccinations are pose a greater threat than they are.

Included in her “wish list” for the incoming government included altering regulations for recently developed shots and halting “unnecessary” immunizations, she stated following the vote on a audio program. At the FDA, Dr. Høeg has according to sources suggested barring adolescent males from obtaining Covid vaccines.

“She is an thorough dogmatist who commences with her conclusions and works backwards to retrofit the evidence in a very deceptive, fraudulent manner,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of fellow dissenters, {like|